SPONSORED

.

Hoth Therapeutics (NASDAQ: HOTH) Is Heating Up – New Site Added As Patient Demand Surges In Trial [Read Now]

Hoth Therapeutics, Inc.

  (NASDAQ: HOTH)

===========================

Prev Close: $0.9968 per share 

Members,

Hoth Therapeutics (NASDAQ: HOTH) is a micro-cap clinical-stage biotech stock back on the radar after a cluster of company updates that matter for near-term momentum (HT-001 trial execution) and longer-term optionality (IP + pipeline breadth).

Market Snapshot 

Hoth Therapeutics (NASDAQ: HOTH) closed at $0.9968 on Tuesday, March 3, 2026, sitting comfortably in the heart of its 52-week range of $0.66 – $2.12. With average daily volume hovering near 446K shares, this microcap biotech offers classic headline-driven volatility—meaning meaningful moves can happen fast on positive catalysts like trial updates, strong data, or IP wins.

At this valuation and size, HOTH has tremendous upside leverage as the story advances. Momentum is building with accelerating enrollment in the HT-001 (CLEER-001) Phase 2a trial—fueled by surging patient demand and the recent addition of a high-impact Miami site—plus standout interim results. 

Add in the obesity program's groundbreaking preclinical edge over semaglutide benchmarks, fresh U.S. patent allowances layering the IP moat, and a lean, focused operation extending runway smartly, and HOTH is primed for rapid re-rating on upcoming data cadences, enrollment milestones, and potential partnerships. This is a classic high-conviction biotech setup where near-term progress can drive outsized gains!

What Changed Recently (The Catalyst Stack)

HT-001 / CLEER-001 Phase 2a: Enrollment Acceleration + New Site Added (Feb 24–25, 2026)

Hoth announced a meaningful expansion of its CLEER-001 Phase 2a clinical trial by adding Regis Clinical Research (Miami, Florida) as a new enrolling site—citing demand outpacing capacity at existing sites. 

The company also reiterated interim signals it says are driving interest, including:

• 100% of open-label cohort patients achieving the primary efficacy endpoint (ARIGA ≤ 1) by week six
• Zero patients requiring EGFR inhibitor dose reduction/discontinuation while on HT-001
• 65%+ reporting meaningful reductions in pain/itching
• No dose-limiting toxicities observed to date 

USPTO Notice of Allowance: Exon-Skipping Patent For Allergic Diseases (Feb 12, 2026)

Hoth reported a U.S. Notice of Allowance covering a dual-mechanism approach involving exon skipping of FC-Epsilon-RI-Beta and MS4A6A modulation. This is an IP strengthener that can improve defensibility and partnering discussions.

“Optionality” Headline: GDNF Obesity/MASLD Preclinical Comparison Vs Semaglutide (Feb 10, 2026)

Hoth highlighted preclinical data suggesting its HT-VA GDNF program outperformed semaglutide across several measures in an obesity model. This is not the core near-term value driver (still preclinical), but it can materially impact attention when the market is hunting obesity narratives. 

Core Program Focus: HT-001

Indication: skin toxicities associated with EGFR inhibitor cancer therapies—an area the company positions as an unmet need (patients can be forced to reduce/discontinue life-saving therapy due to severe dermatologic side effects). 

Trial structure:

• 6-week treatment period and 2-week follow-up
• Open-label cohort using HT-001 2% (n=12 patients)
• Randomized, double-blind portion evaluating 0.5% / 1% / 2% vs placebo (n=140 patients)

Execution signal: adding sites

In microcap biotech, “execution velocity” can matter as much as the science. Adding enrolling sites typically aims to speed enrollment and improve the chances of delivering a complete dataset on schedule. Hoth explicitly framed the new site as a response to enrollment demand. 

The investor deck lists a milestone expectation for a “full data set for open label PK cohort” in Q1 2026.

Watch Our Recent Video Update On Hoth Therapeutics on YouTube👇

Pipeline Overview 

Hoth is working on “multiple shots on goal” across several programs, including: HT-001, HT-KIT, HT-ALZ, BioLexa, HT-004, and HT-VA. 

HT-KIT (Oncology) — Orphan-Designated Program, IND Track

Hoth has emphasized FDA Orphan Drug Designation for HT-KIT and has communicated an IND submission target in the Q4 2026 window (per company slide timeline).

HT-ALZ (Neurology) — 505(b)(2) Formulation Strategy

The company states HT-ALZ uses an already approved drug as the active ingredient and aims to pursue development via the 505(b)(2) pathway, in an oral soluble film format. 

HT-VA (Metabolic) — Preclinical “Attention Magnet”

The February preclinical release is a visibility catalyst, but it remains high risk until translated into clinical development. 

Financial Strength & Smart Capital Strategy

 Per the latest SEC quarterly filing (Form 10-Q for the period ending September 30, 2025):

• Cash & cash equivalents: $7.85M — a solid war chest providing meaningful runway for upcoming milestones
• Total current liabilities: ~$1.01M — super clean balance sheet with minimal obligations
• Shares issued & outstanding: 15.13M (up from 8.04M at Dec 31, 2024) — reflects proactive capital raises to fund acceleration
• Net cash used in operating activities: ~$7.65M over the nine months ended Sept 30, 2025 — typical for an advancing early-stage biotech pushing programs forward

Practical Takeaway: As a high-potential clinical-stage biotech, HOTH is strategically burning cash to drive clinical progress while tapping the markets for non-dilutive funding when needed. 

The recent raises have extended runway and positioned the company to hit key catalysts without unnecessary pressure. With a lean liability profile and focused execution, HOTH is built to capitalize on near-term data readouts and pipeline momentum—dilution is part of the biotech playbook, but here it's clearly being used to build real value and keep the story advancing strong.

What To Watch Next 

Near-term (the big momentum builders):

• More site additions + fresh enrollment updates for CLEER-001 — The recent Regis Clinical Research addition in Miami is already accelerating things amid surging patient demand. Watch for more sites joining the network and explicit enrollment progress reports — these signal explosive interest and faster path to full data!
• Delivery of the open-label dataset — The company’s timeline points to this drop soon. With interim results already showing 100% of patients hitting ARIGA rash severity ≤1 by week six, zero dose reductions, meaningful itch/pain relief, and no dose-limiting toxicities, the full open-label readout could be a major validation moment!
• Clarity on timing and progress for the randomized portion — As outlined in investor materials, this double-blind, placebo-controlled phase is the next big leap. Any updates on startup, dosing arms, or enrollment kickoff will crank up the visibility and potential upside.

Secondary (these could deliver serious fireworks if they land):

• Patent progress: Notice of Allowance → full issuance + follow-on IP layering — Recent allowances (like the exon-skipping therapy for allergic diseases and others in oncology/dermatology) are stacking the deck. Watch for issuances that lock in protection and open doors wider!
• Any partnership/licensing discussions tied to IP or pipeline — With strengthening global IP (China patent for HT-KIT, U.S. allowances, etc.) and hot pipeline assets (HT-001 momentum + obesity program buzz), disclosed talks or deals could spark major re-rating and value creation.
• Financing terms (structure, pricing, runway extension) — Smart, well-timed raises have fueled progress so far. Keep an eye on upcoming moves that extend the runway and support these accelerating catalysts without missing a beat.

These are the fireworks to track—HOTH is building real velocity with strong early signals, patient demand, and IP muscle. The next few months could be electric as these boxes get checked!

Bottom Line

HOTH is firing on all cylinders as a dynamic microcap biotech with exciting near-term catalysts ahead! The HT-001 Phase 2a trial is charging forward with strong execution and a fresh clinical site now enrolling patients — a clear move to ramp up momentum, meet surging demand, and deliver data even faster. 

The bolstered IP portfolio adds serious strength to the lineup, and that eye-catching obesity program headline is turning heads and building buzz across the board. 

With solid clinical progress and smart resource management fueling the engine, HOTH is well-positioned for an exciting run driven by upcoming milestones and growing potential!

As always, we encourage you to conduct your own research and consider how our stock and crypto picks fits into your broader investment strategy.

Join our NEW Channel on Instagram:

CLICK HERE

Sincerely,

The DEXWireNews Team